Loading clinical trials...

Diastology-Guided Management of Decompensated Heart Failure | Clinical Trials | Clareo Health

UNKNOWNNA

Diastology-Guided Management of Decompensated Heart Failure

DiastologY-Guided MaNAgement of DecoMpensated Heart Failure: A Pilot RandomIzed, Controlled Trial

NCT06131008•McMaster University

Summary

More than 30% of people hospitalized with decompensated heart failure return to the hospital within 90 days. Emerging evidence suggests that hemodynamic monitoring with guided management may enhance prognosis and management. Hemodynamic monitoring with echocardiography using diastology and an evidence-informed therapeutic protocol have the potential to achieve this aim in a minimally invasive manner.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Age ≥18 years at the time of enrolment
•2. Decompensated heart failure with reduced ejection fraction (≤40%)
•3. Sinus rhythm without conduction abnormalities (second-degree Mobitz II, third-degree, permanent pacemaker)
•4. Written informed consent from either the patient or a substitute decision maker

Exclusion Criteria

•1. Mitral annular calcification (at least moderate or severe)
•2. Moderate or severe aortic or mitral valvular heart disease, or history of prosthetic mitral valve
•3. Atrial fibrillation or flutter
•4. History of non-diagnostic echocardiogram
•5. Hemodialysis

Key Dates

Start Date

November 6, 2023

Primary Completion Date

April 8, 2024

Completion Date

July 31, 2024

Last Updated

November 14, 2023

Enrollment

ESTIMATED participants

Conditions

Heart FailureDiastolic Dysfunction

Interventions

Diastology

DIAGNOSTIC_TEST

Diastology-Guided Diuresis

BEHAVIORAL

Usual Care

BEHAVIORAL

Contacts

Kevin J Um, MD

CONTACT

905-521-2100 kevin.um@dataparty.ca

Emilie P Belley-Cote, MD PhD

CONTACT

905-521-2100 emilie.belley-cote@phri.ca

ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies

NCT07191730

CardiotoxicityHeart Failure+2 more

View study

RECRUITINGNA

ReDS-guided Decongestion Strategy in Patients Hospitalized for Heart Failure

NCT07484009

Acute Heart Failure (AHF)Heart Failure (for Example, Fluid Overload)+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 14, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Diastology-Guided Management of Decompensated Heart Failure

Inclusion Criteria

Exclusion Criteria

ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies

ReDS-guided Decongestion Strategy in Patients Hospitalized for Heart Failure

Homocysteine and Early Diastolic Dysfunction in Newly Diagnosed Hypertension

Hemodynamic Monitoring to Prevent Adverse Events foLlowing cardiOgenic Shock Trial

Proof-of-concept of a Behavioral Intervention to Improve the Cardiovascular Health of People Living With HIV

Autologous Induced Pluripotent Stem Cells of Cardiac Lineage for Congenital Heart Disease